OCUL Ocular Therapeutix Inc

Voya Investment Management LLC has reduced its stake in Ocular Therapeutix (NASDAQ:OCUL) by 36.7% in the third quarter of 2025, selling 107,143 shares and retaining 184,427 shares valued at $2.16 million. Despite insider selling, analyst sentiment remains positive with a "Moderate Buy" consensus and an average price target of $22.56 against a recent share price of $12.56. Other institutional investors have also adjusted their holdings in the biopharmaceutical company.

Assenagon Asset Management S.A. significantly reduced its stake in Ocular Therapeutix, Inc. by selling 148,100 shares, bringing its total holdings to 45,600 shares. This move by Assenagon comes as other institutional investors like Adage Capital Partners and Invesco Ltd. increased their positions, while company insiders also sold a combined 31,287 shares. Analysts currently rate Ocular Therapeutix with a "Moderate Buy" and a consensus target price of $22.56.

Ocular Therapeutix (NASDAQ:OCUL) shares have moved above their 50-day moving average, trading at $12.71 against a 50-day MA of $12.28, on heavy volume. The company holds a "Moderate Buy" consensus from analysts with a target price of $22.56, despite remaining unprofitable and recent insider share sales. Institutional investors own approximately 59% of the stock, while insiders have sold over 31,000 shares in the last 90 days.

Ocular Therapeutix's (OCUL) stock dropped 10.9% after the company announced its plan to pursue a single-trial New Drug Application (NDA) for its wet AMD candidate AXPAXLI, leveraging positive year-one data from the SOL-1 Phase 3 trial. This strategic pivot, influenced by FDA feedback, could accelerate market entry but also heightens regulatory risks around the Q1 2026 data readout. The change sharpens the near-term catalyst while concentrating the company's investment narrative on AXPAXLI's success.

Ocular Therapeutix (OCUL) has accelerated its FDA filing plan for AXPAXLI in wet AMD based on positive Phase 3 data, leading to a valuation that suggests it is 43.2% undervalued. Despite a weak 5-year return, the company has shown strong long-term momentum with a 3-year total shareholder return of 395.31% and analysts see considerable upside. The potential approval of AXPAXLI with a superiority label and longer dosing intervals could capture significant market share and drive substantial revenue growth in the expanding market for ophthalmic disorders.

Ocular Therapeutix (OCUL) has accelerated its FDA filing for AXPAXLI in wet AMD based on positive Phase 3 data, leading to a "narrative" valuation of $24.17 against its current $13.72 share price, suggesting it is undervalued. The drug, potentially offering longer dosing intervals and superiority, could capture significant market share in the growing wet AMD market. Although the stock has seen substantial gains, analysts still see considerable upside, raising questions about whether the market has fully priced in its potential.